Milford medical device company RenalGuard Solutions is claiming a recent clinical study has found a new device to help treat heart failure patients.
The device, the RenalGuard-Guided Diuretic Therapy, was proven to optimize fluid management in acute decompensated heart failure patients while alleviating related symptoms, the company announced Tuesday.
According to the company, the device is designed to allow doctors to increase the dose of diuretics without increasing the risk of diuretic resistance while attempting to restore healthy fluid levels to the kidneys after acute decompensated heart failure.
In the first in-human clinical trials, patients underwent 24 hours of standard diuretic therapy followed by 24 hours in conjunction with RenalGuard’s therapy. The results were a significant improvement in breathing patterns and diuretic efficiency among patients treated with RenalGuard.
After a full day of standard therapy, the average urine output was 1,961 mL. After 24 hours with RenalGuard therapy, the average urine output increased to 4,771 mL, the company said.
